There is public documentation of 16 announced deals since September 30, 2025 between the administration and pharmaceutical manufacturers that commit to MFN-aligned pricing.
Source summary
The White House announced the launch of TrumpRx.gov, a website that offers patients discounted prices on branded medicines by matching the lowest prices paid by other developed countries (most‑favored‑nation or MFN pricing). The launch includes deals from AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer and lists price reductions for 40 costly drugs, including steep cuts for Ozempic, Wegovy, fertility medicines, and insulin. The fact sheet notes prior executive actions and deals announced since 2025, and a separate
U.S. agreement with the
U.K. intended to raise net U.K. drug prices by 25%.